Nektar Therapeutics/ US6402681083 /
| 2024-05-10 10:00:00 PM | Chg. +0.1600 | Volume | Bid1:02:26 AM | Ask1:02:26 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 1.7600USD | +10.00% | 2.36 mill. Turnover: 3.96 mill. |
1.7900Bid Size: 24,900 | 1.8300Ask Size: 100 | 322.6 mill.USD | 0.00% | - |
Assets
|
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 47.5000 | 48.9000 | 65 | 59.7000 | 60.5000 | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | - | - | - | - | - | ||||||
| Fixed Assets | - | - | - | - | - | ||||||
| Inventories | 10.7000 | 11.4000 | 12.7000 | 15.3000 | 15.8000 | ||||||
| Accounts Receivable | 5 | 43.2000 | 36.8000 | 38.9000 | 22.5000 | ||||||
| Cash and Cash Equivalents | 4.8000 | 194.9000 | 96.4000 | 199 | 25.2000 | ||||||
| Current Assets | 326.8000 | 1,437.7000 | 1,421.6000 | 1,138 | 795.6000 | ||||||
| Total Assets | 508.9000 | 2,150.2000 | 1,977.4000 | 1,538.8000 | 1,117.2000 | ||||||
Liabilities
|
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 4.8000 | 5.9000 | 19.2000 | 22.1000 | 9.7000 | ||||||
| Long-term debt | 245.2000 | 247 | - | - | - | ||||||
| Liabilities to Banks | 249.4000 | 251.2000 | 252.9000 | 0.0000 | 0.0000 | ||||||
| Provisions | 19.5000 | 47.6000 | 51.3000 | 65.1000 | 42.3000 | ||||||
| Liabilities | 421 | 432.6000 | 572 | 461.5000 | 437.7000 | ||||||
| Share Capital | .0150 | .0170 | .0170 | .0180 | .0190 | ||||||
| Total Equity | 87.8000 | 1,717.6000 | 1,405.4000 | 1,077.3000 | 679.5000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 508.9000 | 2,150.2000 | 1,977.4000 | 1,538.8000 | 1,117.2000 | ||||||
Income Statement
|
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 307.7000 | 1,193.3000 | 114.6000 | 152.9000 | 101.9000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -59.6000 | 687.9000 | -440 | -425.1000 | -446.1000 | ||||||
| Interest Income | -40.9000 | -42.7000 | -46.4000 | -37.2000 | -47.3000 | ||||||
| Income Before Taxes | -96.1000 | 682.7000 | -440.1000 | -443.9000 | -523.3000 | ||||||
| Income Taxes | .6000 | 1.4000 | .6000 | .5000 | .6000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | -96.7000 | 681.3000 | -440.7000 | -444.4000 | -523.8000 | ||||||
Per Share
Cash Flow
|
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -80.4000 | 718.2000 | -328.7000 | -313.3000 | -412.7000 | ||||||
| Cash Flow from Investing Activities | -28.8000 | -1,379.9000 | 206.9000 | 496.2000 | 202.8000 | ||||||
| Cash Flow from Financing | 54.4000 | 852 | 23.4000 | -80.4000 | 36.2000 | ||||||
| Decrease / Increase in Cash | -54.9000 | 190.1000 | -98.5000 | 102.6000 | -173.7000 | ||||||
| Employees | 509 | 618 | 723 | 718 | 740 | ||||||
